帕金森病<sup>18</sup>F-FDG PET成像研究进展

摘要
图/表
参考文献(30)
相关文章 (9)

全文: PDF (687 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要帕金森病是一种常见的神经系统变性疾病，早期诊断和鉴别诊断历来是神经科临床工作的难点之一，随着功能影像学的发展，18F-氟脱氧葡萄糖（FDG）正电子发射断层扫描成像（PET）成为帕金森病临床诊疗中的重要工具。本文回顾了目前¹⁸F-FDG PET成像常用数据分析方法及帕金森病临床症状和脑代谢之间的研究结果，并对¹⁸F-FDG PET成像在帕金森病的鉴别诊断、早期诊断和疗效评估以及未来发展方向进行综述。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	陈志琳汪锡金

关键词 ：帕金森病, ¹⁸F-FDG PET, 脑代谢网络模式, 认知功能损害, 快速眼动睡眠行为障碍

Abstract：Parkinson's disease is a common neurological degenerative disease, early diagnosis and differential diagnosis are the most difficult points toneurologist. With the development of functional imaging, ¹⁸F labelled fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging has become an important tool for Parkinson's disease. This artical first review the current analytic approaches to 18F-FDG PET imaging data and then discuss how ¹⁸F-FDG PET studies have advanced understanding of the relation between the clinical symptoms and brain metabolism of Parkinson's disease. In addition,the value of 18F-FDG PET imaging in differential diagnosis, early diagnosis,the evaluation of treatment effects and the future development direction are also reviewed.

Key words： Parkinson's disease ¹⁸F-FDG PET Metabolic pattern Cognitive impairment Idiopathic rapid eye movement sleep behavior disorders

基金资助:国家自然科学基金资助项目（81671273）。

通讯作者: 汪锡金（1971.1-），男，博士，副主任医师，硕士研究生导师；研究方向：神经内科疾病。

引用本文:

陈志琳汪锡金. 帕金森病¹⁸F-FDG PET成像研究进展[J]. 中国医药导报, 2017, 14(24): 42-45.
CHEN Zhilin WANG Xijin. ¹⁸F-FDG PET imaging in Parkinson's disease. 中国医药导报, 2017, 14(24): 42-45.

链接本文:

http://www.yiyaodaobao.com.cn/CN/ 或 http://www.yiyaodaobao.com.cn/CN/Y2017/V14/I24/42

[1] Postuma RB，Berg D，Stern M，et al. MDS clinical diagnostic criteria for Parkinson's disease [J]. Mov Disord，2015， 30（12）：1591-1601.
[2] Adler CH，Beach TG，Hentz JG，et al. Low clinical diagnostic accuracy of early vs advanced Parkinson disease：clinicopathologic study [J]. Neurology，2014，83（5）：406-412.
[3] Eidelberg D，Moeller JR，Dhawan V，et al. The metabolic topography of parkinsonism [J]. J Cereb Blood Flow Metab，1994，14（5）：783-801.
[4] Ma Y，Tang C，Spetsieris PG，et al. Abnormal metabolic network activity in Parkinson's disease： test-retest reproducibility [J]. J Cereb Blood Flow Metab，2007，27（3）：597-605.
[5] Niethammer M，Eidelberg D. Metabolic brain networks in translational neurology： concepts and applications [J]. Ann Neurol ，2012，72（5）：635-647.
[6] Wu P，Wang J，Peng S，et al. Metabolic brain network in the Chinese patients with Parkinson's disease based on 18F-FDG PET imaging [J]. Parkinsonism Relate Disord，2013， 19（6）：622-627.
[7] Holtbernd F，Ma Y，Peng S，et al. Dopaminergic correlates of metabolic network activity in Parkinson's disease [J]. Hum Brain Mapp，2015，36（9）：3575-3585.
[8] Isaias IU，Marotta G，Hirano S，et al. Imaging essential tremor[J]. Mov Disord，2010，25（6）：679-686.
[9] Mure H，Hirano S，Tang CC，et al. Parkinson's disease tremor-related metabolic network：characterization，progression，and treatment effects [J]. NeuroImage，2011，54（2）：1244-1253.
[10] Ko JH，Mure H，Tang CC，et al. Parkinson's disease： increased motor network activity in the absence of movement [J]. J Neuro Sci，2013，33（10）：4540-4549.
[11] Spetsieris PG，Ko JH，Tang CC，et al. Metabolic resting-state brain networks in health and disease [J]. Proc Nati Acad Sci USA，2015，112（8）：2563-2568.
[12] Aarsland D，Bronnick K，Williams-Gray C，et al. Mild cognitive impairment in Parkinson disease：a multicenter pooled analysis [J]. Neurology，2010，75（12）：1062-1069.
[13] Litvan I，Aarsland D，Adler CH，et al. MDS Task Force on mild cognitive impairment in Parkinson's disease：critical review of PD-MCI [J]. Mov Disord，2011，26（10）：1814-1824.
[14] Huang C，Mattis P，Tang C，et al. Metabolic brain networks associated with cognitive function in Parkinson's disease [J]. NeuroImage，2007，34（2）：714-723.
[15] Meles SK，Tang CC，Teune LK，et al. Abnormal metabolic pattern associated with cognitive impairment in Parkinson's disease：a validation study [J]. J Cereb Blood Flow Metab，2015，35（9）：1478-1484.
[16] Litvan I，Goldman JG，Troster AI，et al. Diagnostic criteria for mild cognitive impairment in Parkinson's disease：movement disorder society task force guidelines [J]. Mov Disord，2012，27（3）：349-356.
[17] Eckert T，Tang C，Ma Y，et al. Abnormal metabolic networks in atypical parkinsonism [J]. Mov Disord，2008，23（5）：727-733.
[18] Niethammer M，Tang CC，Feigin A，et al. A disease-specific metabolic brain network associated with corticobasal degeneration [J]. Brain，2014，137（Pt11）：3036-3046.
[19] Tang CC，Poston KL，Eckert T，et al. Differential diagnosis of parkinsonism： a metabolic imaging study using pattern analysis [J]. Lancet Neurol 2010，9（2）：149-158.
[20] Tripathi M，Tang CC，Feigin A，et al. Automated differential diagnosis of early parkinsonism using metabolic brain networks：a validation study [J]. J Nucl Med，2016， 57（1）：60-66.
[21] Mudali D，Teune LK，Renken RJ，et al. Classification of Parkinsonian syndromes from FDG-PET brain data using decision trees with SSM/PCA features [J]. Comput Math Methods Med，2015，2015：136921.
[22] Heller J，Brcina N，Dogan I，et al. Brain imaging findings in idiopathic REM sleep behavior disorder （RBD）-A systematic review on potential biomarkers for neurodegeneration [J]. Sleep Med Rev，2017，34：23-33.
[23] Holtbernd F，Gagnon JF，Postuma RB，et al. Abnormal metabolic network activity in REM sleep behavior disorder [J]. Neurology， 2014，82（7）：620-627.
[24] Wu P，Yu H，Peng S，et al. Consistent abnormalities in metabolic network activity in idiopathic rapid eye movement sleep behaviour disorder [J]. Brain，2014，137（Pt 12）：3122-3128.
[25] Asanuma k，Tang C，Ma Y，et al. Network modulation in the treatment of Parkinson's disease [J]. Brain，2006，129（Pt 10）：2667-2678.
[26] Feigin A，Fukuda M，Dhawan V，et al. Metabolic correlates of levodopa response in Parkinson's disease [J]. Neurology，2001，57（11）：2083-2088.
[27] Torst M，Su S，Su P，et al. Network modulation by the subthalamic nucleus in the treatment of Parkinson's disease [J]. Neuroimage，2006，31（1）：301-307
[28] Feigin A，Kplitt MG，Tang C，et al. Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson's disease [J]. Proc Natl Acad Sci USA，2007，104（49）：19559-19564.
[29] Ko JH，Lerner RP，Eidelberg D. Effects of levodopa on regional cerebral metabolism and blood flow [J]. Mov Disord，2015，30（1）：54-63.
[30] Ko JH，Feigin A，Mattis PJ，et al. Network modulation following sham surgery in Parkinson's disease [J]. J Clin Invest，2014，124（8）：3656-3666.